Immuneering Corporation (NASDAQ:IMRX) Stock Has Consensus Price Target of $15.71 According to Analysts

Key Points

• Analysts have a consensus “Buy” rating on Immuneering, with a one-year average price target of $15.71. Ratings include four buys, two strong buys, and one sell.
• Immuneering shares opened at $3.74, near their 52-week low of $3.60, while the company’s latest quarterly loss of $0.27 per share slightly missed the $0.26 consensus estimate.
• Institutional investors own 67.65% of the company, and Immuneering is advancing IMM-1-104, an oral therapy targeting RAS-mutated solid tumors including pancreatic cancer.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have received an average rating of "Buy" from the seven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $15.71.

Several analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating on shares of Immuneering in a research note on Thursday, August 27th. Cantor Fitzgerald began coverage on shares of Immuneering in a research note on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 price target for the company. UBS Group set a $14.00 price objective on shares of Immuneering in a report on Thursday, August 6th. Chardan Capital upgraded Immuneering to a "strong-buy" rating in a research note on Monday, August 3rd. Finally, Needham & Company LLC increased their target price on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a report on Monday, July 20th.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $3.74 on Friday. The company has a market capitalization of $241.98 million, a price-to-earnings ratio of -3.60 and a beta of 0.46. Immuneering has a 1-year low of $3.60 and a 1-year high of $8.48. The business has a 50-day moving average of $4.61 and a 200-day moving average of $4.86.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Research analysts expect that Immuneering will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently modified their holdings of IMRX. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Immuneering in the 4th quarter worth approximately $33,000. Integrated Wealth Concepts LLC bought a new stake in shares of Immuneering during the 2nd quarter worth $34,000. Levin Capital Strategies L.P. acquired a new stake in shares of Immuneering during the first quarter worth $53,000. Focus Financial Network Inc. acquired a new stake in shares of Immuneering during the second quarter worth $62,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Immuneering during the first quarter valued at $67,000. Institutional investors own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancers driven by abnormal signaling through the RAS/MAPK pathway. The company applies computational biology and its Deep Cyclic Inhibition approach to design therapies intended to provide sustained pathway suppression while allowing normal cells periods of recovery.

Immuneering's lead product candidate, IMM-1-104, is an oral therapy being developed for patients with RAS-mutated solid tumors, including pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.